PT1544299E - Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular - Google Patents

Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular Download PDF

Info

Publication number
PT1544299E
PT1544299E PT05001328T PT05001328T PT1544299E PT 1544299 E PT1544299 E PT 1544299E PT 05001328 T PT05001328 T PT 05001328T PT 05001328 T PT05001328 T PT 05001328T PT 1544299 E PT1544299 E PT 1544299E
Authority
PT
Portugal
Prior art keywords
treatment
eye disorders
vegf receptor
vascular permeability
disorders characterized
Prior art date
Application number
PT05001328T
Other languages
English (en)
Inventor
Nicholas J Papadopoulos
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1544299(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT1544299E publication Critical patent/PT1544299E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
PT05001328T 1999-06-08 2000-05-23 Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular PT1544299E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (1)

Publication Number Publication Date
PT1544299E true PT1544299E (pt) 2009-03-18

Family

ID=22480568

Family Applications (2)

Application Number Title Priority Date Filing Date
PT00932721T PT1183353E (pt) 1999-06-08 2000-05-23 Polipeptidos quimericos modificados com propriedades farmacocineticas melhoradas
PT05001328T PT1544299E (pt) 1999-06-08 2000-05-23 Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT00932721T PT1183353E (pt) 1999-06-08 2000-05-23 Polipeptidos quimericos modificados com propriedades farmacocineticas melhoradas

Country Status (33)

Country Link
EP (2) EP1544299B1 (pt)
JP (2) JP4723140B2 (pt)
KR (1) KR100659477B1 (pt)
CN (3) CN101433715B (pt)
AT (2) ATE417928T1 (pt)
AU (2) AU779303B2 (pt)
BE (1) BE2013C029I2 (pt)
BR (2) BRPI0011407B8 (pt)
CA (1) CA2376379C (pt)
CY (2) CY1108883T1 (pt)
CZ (2) CZ303656B6 (pt)
DE (2) DE60019415T2 (pt)
DK (2) DK1544299T3 (pt)
ES (2) ES2319305T3 (pt)
FR (1) FR13C0028I2 (pt)
HK (3) HK1043388A1 (pt)
HR (1) HRP20010908B1 (pt)
HU (3) HU230159B1 (pt)
IL (3) IL146890A0 (pt)
LT (1) LTC1183353I2 (pt)
LU (1) LU92195I2 (pt)
ME (2) ME00024B (pt)
MX (1) MXPA01012630A (pt)
NO (3) NO330775B1 (pt)
NZ (1) NZ515913A (pt)
PL (1) PL208247B1 (pt)
PT (2) PT1183353E (pt)
RS (1) RS50073B (pt)
RU (1) RU2265661C2 (pt)
SK (1) SK287332B6 (pt)
UA (1) UA74146C2 (pt)
WO (1) WO2000075319A1 (pt)
ZA (1) ZA200110068B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
WO2004108069A2 (en) 2002-05-04 2004-12-16 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
PL1608685T3 (pl) 2003-03-28 2007-07-31 Regeneron Pharma Antagoniści VEGF do leczenia cukrzycy
ES2616749T3 (es) 2003-05-16 2017-06-14 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
ES2831031T3 (es) * 2003-05-16 2021-06-07 Acorda Therapeutics Inc Proteínas de fusión para el tratamiento del CNS
WO2004106378A2 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
CA2566731C (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
CA2569108C (en) 2004-06-08 2012-08-21 Chengdu Kanghong Biotechnologies Co. Ltd Angiogenesis-inhibiting chimeric protein and the use
AU2005254058A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for the treatment of human cancer
AU2005265071A1 (en) * 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
MX2007001241A (es) 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
PL2229956T3 (pl) 2004-09-13 2013-09-30 Genzyme Corp Konstrukty multimeryczne
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
WO2006104852A2 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
PT1962895E (pt) † 2005-12-16 2013-03-28 Regeneron Pharma Utilização terapêutica de um antagonista dll4 e de um inibidor fcev para inibição de crescimento de tumores
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
MX2008016124A (es) 2006-06-16 2009-01-20 Regeneron Pharma Formulaciones antagonistas de vegf adecuadas para la administracion intravitreal.
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
EP2450442B1 (en) 2006-10-10 2017-07-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
ES2836948T3 (es) 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
AR081361A1 (es) * 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
EP3327032A1 (en) 2010-08-06 2018-05-30 Genzyme Corporation Vegf antagonist compositions and uses thereof
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
DK2846836T3 (da) 2012-05-07 2019-11-11 Allergan Inc Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
EP3065761B1 (en) 2013-11-05 2020-01-08 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
EP3143044A1 (en) 2014-05-12 2017-03-22 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
ES2732925T3 (es) 2014-07-18 2019-11-26 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
SI3230316T1 (sl) 2014-12-11 2022-05-31 Bayer Healthcare Llc Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
KR102354198B1 (ko) 2015-11-18 2022-01-20 에스아이오2 메디컬 프로덕츠, 인크. Vegf-길항제의 액체 제제를 포함하는 사전-충전된 제약 패키지
US11654046B2 (en) 2015-11-18 2023-05-23 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
CA3005391A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
LT3384049T (lt) 2015-12-03 2023-09-11 Regeneron Pharmaceuticals, Inc. Genetinių variacijų susiejimo su klinikiniais rezultatais būdai pacientams, sergantiems amžine geltonosios dėmės degeneracija, gydytiems anti-vegf
JP6953433B2 (ja) 2016-01-26 2021-10-27 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CA3067735A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
DK3717636T3 (da) 2017-11-27 2023-05-30 4D Molecular Therapeutics Inc Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
JP7339248B2 (ja) 2017-11-30 2023-09-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用
CN117405806A (zh) * 2017-12-13 2024-01-16 里珍纳龙药品有限公司 管理层析柱床支架的装置和系统及相关方法
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
CA3150481A1 (en) 2019-09-03 2021-03-11 Amgen Inc. Injection device for drug delivery and packaging for the injection device
US20210077645A1 (en) 2019-09-16 2021-03-18 Amgen Inc. Method for external sterilization of drug delivery device
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
NZ781143A (en) * 2019-12-06 2023-05-26 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
JP2023505216A (ja) 2019-12-06 2023-02-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆミニトラップおよびそれらの使用方法
JP2023514325A (ja) 2020-02-24 2023-04-05 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌中に使用するための容器及びシステム
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
HUP0201515A3 (en) 2004-12-28
EP1183353B1 (en) 2005-04-13
EP1544299A1 (en) 2005-06-22
HUP0201515A2 (en) 2002-08-28
CN103349781B (zh) 2015-04-01
HK1185798A1 (en) 2014-02-28
CA2376379C (en) 2007-08-07
NO2013010I1 (no) 2013-06-17
IL190234A0 (en) 2008-11-03
DK1544299T3 (da) 2009-03-23
CN101433715A (zh) 2009-05-20
NO330775B1 (no) 2011-07-11
DE60019415D1 (de) 2005-05-19
BRPI0011407B1 (pt) 2018-09-25
BR0011407A (pt) 2002-04-02
RS50073B (sr) 2009-01-22
JP2003501089A (ja) 2003-01-14
HU230159B1 (hu) 2015-09-28
FR13C0028I1 (fr) 2013-06-14
HRP20010908B1 (en) 2006-05-31
RU2265661C2 (ru) 2005-12-10
HRP20010908A2 (en) 2005-04-30
HK1132653A1 (en) 2010-03-05
AU2005201365B2 (en) 2007-08-09
AU779303B2 (en) 2005-01-13
KR20020019070A (ko) 2002-03-09
CZ20014387A3 (cs) 2002-10-16
CY1108883T1 (el) 2014-07-02
NO20100656L (no) 2002-02-08
NO332559B1 (no) 2012-10-29
IL146890A (en) 2008-07-08
NO20016036L (no) 2002-02-08
EP1183353A1 (en) 2002-03-06
JP4723140B2 (ja) 2011-07-13
DE60041159D1 (de) 2009-01-29
NO2013010I2 (no) 2013-05-15
ATE417928T1 (de) 2009-01-15
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
JP2011024595A (ja) 2011-02-10
CY2013019I1 (el) 2015-11-04
CN101433715B (zh) 2013-04-17
ZA200110068B (en) 2002-12-06
LTPA2013009I1 (lt) 2013-06-25
LTC1183353I2 (lt) 2023-02-27
PL352246A1 (en) 2003-08-11
PT1183353E (pt) 2005-06-30
WO2000075319A1 (en) 2000-12-14
ES2319305T3 (es) 2009-05-06
MEP3208A (xx) 2010-02-10
DE60019415T2 (de) 2006-03-09
CZ302689B6 (cs) 2011-09-07
CY2013019I2 (el) 2015-11-04
UA74146C2 (uk) 2005-11-15
IL146890A0 (en) 2002-08-14
AU2005201365A1 (en) 2005-04-28
CN1369009A (zh) 2002-09-11
HK1043388A1 (en) 2002-09-13
SK17522001A3 (sk) 2003-04-01
MXPA01012630A (es) 2002-07-22
ATE293164T1 (de) 2005-04-15
PL208247B1 (pl) 2011-04-29
EP1544299B1 (en) 2008-12-17
CN100523187C (zh) 2009-08-05
SK287332B6 (sk) 2010-07-07
NO20016036D0 (no) 2001-12-10
NZ515913A (en) 2004-01-30
CN103349781A (zh) 2013-10-16
ME00024B (me) 2010-02-10
JP5273746B2 (ja) 2013-08-28
FR13C0028I2 (fr) 2014-05-16
CZ303656B6 (cs) 2013-01-30
HUS1300052I1 (hu) 2016-08-29
BE2013C029I2 (pt) 2019-03-06
LU92195I2 (fr) 2013-07-15
HU229156B1 (en) 2013-09-30
YU86901A (sh) 2004-05-12
BRPI0011407B8 (pt) 2021-05-25
KR100659477B1 (ko) 2006-12-20
ES2237429T3 (es) 2005-08-01
CA2376379A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
PT1544299E (pt) Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
ATE412185T1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
EA200400518A1 (ru) Способы лечения глазных неоваскулярных заболеваний
CA2248087A1 (en) Improved vision through photodynamic therapy of the eye
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
DE602006002135D1 (de) Verwendung von Naloxon zur Behandlung von Essstörungen
DK2407536T3 (da) Adp-ribosyltransferase-fusionsvariantproteiner
HU0104018D0 (en) Use of antagonists of nr2b subtype of nmda receptor for medical treatment
WO2006091666A3 (en) Methods and compositions for treating conditions of the eye
MX2007004622A (es) Acido 5,6,7-trihidroxiheptanoico y analogos para el tratamiento de enfermedades oculares y enfermedades asociadas con respuestas hiperproliferantes y angiogenicas.
DE60008151D1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
WO2005058911A3 (en) Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
AU3360000A (en) Use of 4-amino pyridine for treatment of peripheral neuropathies
FR2816633B1 (fr) Methode de criblage d'agents susceptibles de traiter l'obesite